CCWM
LXRX icon

Cassaday & Co Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.56K Buy
+1,000
New +$1.45K ﹤0.01% 1094

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cassaday & Co Wealth Management's LXRX Position: Q1 2026 in Review

Cassaday & Co Wealth Management opened a new position in Lexicon Pharmaceuticals (LXRX) in Q1 2026: 1,000 shares worth $1.56K. The stake represents ﹤0.01% of the portfolio and ranks #1094 among its holdings.

136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Cassaday & Co Wealth Management held 1,000 shares of Lexicon Pharmaceuticals worth $1.56K as of Q1 2026.
  • Lexicon Pharmaceuticals was a new Cassaday & Co Wealth Management position in Q1 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q1 2026, its #1094 holding.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.